Dynavax Technologies Corporation news

   Watch this stock
Showing stories 11 - 20 of about 91   

Articles published

DVAX 14.86 -0.24 (-1.59%)
price chart
Company Update on High Short Interest:Power Solutions Inte , Dynavax ...
Dynavax Technologies Corp (NASDAQ:DVAX): Each share of Dynavax Technologies Corp is priced at $14.39, which is 32.8% below the 52-week high.
Dynavax Technologies Q2 Loss Wider than Expected, Sales Beat
Dynavax Technologies Corporation (DVAX - Snapshot Report) reported a loss of 9 cents per share in the second quarter of 2014, flat with the year-ago quarter but wider than the Zacks Consensus Estimate of a loss of 6 cents.
Related articles »  
Dynavax Technologies Corporation (DVAX): Dynavax: Embarking On A Run ...
Dynavax (NASDAQ:DVAX) will require a lot of patience. The stock will require about as much patience as has ever been asked of you as an investor.
Dynavax: Assembling The A-Team
As I noted earlier this year, on Thursday, March 21, 2013, Dynavax Technologies Corporation (NASDAQ:DVAX) announced that David Novack joined the company as its Senior Vice President, Operations and Quality, effective March 25, 2013.
Related articles »  
Fast Moving Stocks: Johnson & Johnson (NYSE:JNJ), Dynavax Technologies ...
On 5 November Dynavax Technologies Corporation (NASDAQ:DVAX) reported financial results for the third quarter ended September 30, 2014.
Dynavax Technologies Corporation (DVAX) news: Dynavax drops request for ...
Dynavax (DVAX +1.7%) withdraws its application for the European approval of the company's Hepatitis B vaccine Heplisav after the European Medicines Agency (EMA) indicated that the product's safety database is too small to rule out the risk of less ...
Dynavax Withdraws MAA on Heplisav  Zacks.com
Dynavax Withdraws MAA on Heplisav - Analyst Blog  NASDAQ
Related articles »  
Dynavax Technologies Corporation (DVAX): Insiders Are Buying Dynavax
In Europe, Dynavax' Marketing Authorization Application for Heplisav is currently under review by the European Medicines Agency.
Notable Runners - Dynavax Technologies Corporation (NASDAQ:DVAX ...
Miami, Florida - Oct 07, 2014 - (Tech Sonian) �Dynavax Technologies Corporation (NASDAQ:DVAX) reported its financial results for the first quarter ended March 31, 2014.
Related articles »  
Dynavax Technologies Corporation (DVAX): Getting Ultra-Bullish On Dynavax
Dynavax Technologies Corporation is a clinical-stage biopharma that develops novel products to prevent and treat infectious and inflammatory diseases and cancer.
Related articles »  
Morning Buzz - Cytori Therapeutics Inc (NASDAQ:CYTX), Dynavax ...
Dynavax Technologies Corporation (NASDAQ:DVAX) released initiation of a phase 1/2 clinical trial to assess the safety and preliminary efficacy of SD-101, an investigational Toll-like receptor (�TLR�) 9 agonist, in adults with untreated low-grade B-cell ...
Related articles »